Agency Business briefs

Share this article:

Sudler & Hennessey launched a new website at The site, said APAC/EMEA CEO Max Jackson, “displays our unique culture around the globe.”

Philadelphia creative shop Singularity Design acquired the web, app and video production shop PoinTaken, naming its founder, Calvin Butts, Jr., VP innovations. PoinTaken focuses on interactive healthcare and med ed. Singularity's sibling shops include CMI, Compas and InfoCures. 

PR giant Edelman is looking to build its healthcare practice in China, moving Rebecca Slotnick to Shanghai as senior director of health. She most recently led external corporate communications efforts for global pharmas' businesses in emerging markets from Edelman's New York office. 

Ruane Communications, a Chicago-based PR firm, landed Florida-based PediaVision, which offers screening technology for detecting vision problems in kids. 

Cambridge BioMarketing named Guido Baratta creative director, Interaction. Before joining the Cambridge, MA, healthcare marketing shop, he was creative at Boston's Isobar and  associate creative director at Molecular, also of Beantown.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?